August 26, 2024 04:26 AM EDTUpdated 06:40 AM
Financing
Startups

Pep­tide biotech MBX sub­mits IPO plans, mak­ing a trio of post-La­bor Day Nas­daq hope­fuls

Kyle LaHucik

Senior Reporter

In­di­ana biotech start­up MBX Bio­sciences filed for an ini­tial pub­lic of­fer­ing on Fri­day night.

It be­came the third clin­i­cal-stage drug de­vel­op­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Cor­rect­ed: Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-L1

Neu­ro­crine culls Phase 2 neu­ropsych med af­ter fail­ing to val­i­date ear­li­er da­ta

Bicara, Zenas and MBX rekin­dle IPO mar­ket with rare Fri­day triple­head­er

Au­rinia re­struc­tures board, bring­ing in Kevin Tang and keep­ing CEO

A service from the Financial Times